Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy

Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Franquiz, Miguel J, Short, Nicholas J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027838/
https://www.ncbi.nlm.nih.gov/pubmed/32103893
http://dx.doi.org/10.2147/BTT.S202746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027838/
https://www.ncbi.nlm.nih.gov/pubmed/32103893
http://dx.doi.org/10.2147/BTT.S202746

Ejemplares similares